

Christoph Correll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/344910/publications.pdf>

Version: 2024-02-01

589
papers

46,234
citations

1301

109
h-index

2953

189
g-index

610
all docs

610
docs citations

610
times ranked

26816
citing authors

#	ARTICLE	IF	CITATIONS
1	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , 2011, 10, 52-77.	10.4	1,767
2	How mental health care should change as a consequence of the COVID-19 pandemic. <i>Lancet Psychiatry</i> , 2020, 7, 813-824.	7.4	1,101
3	Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. <i>World Psychiatry</i> , 2017, 16, 163-180.	10.4	1,082
4	Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. <i>Molecular Psychiatry</i> , 2022, 27, 281-295.	7.9	967
5	Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1765.	7.4	867
6	Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. <i>World Psychiatry</i> , 2015, 14, 339-347.	10.4	858
7	Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nature Reviews Endocrinology</i> , 2012, 8, 114-126.	9.6	832
8	The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. <i>Lancet Psychiatry</i> , 2019, 6, 675-712.	7.4	815
9	Schizophrenia. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15067.	30.5	724
10	Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies. <i>American Journal of Psychiatry</i> , 2004, 161, 414-425.	7.2	653
11	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , 2011, 10, 138-151.	10.4	631
12	Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. <i>American Journal of Psychiatry</i> , 2016, 173, 362-372.	7.2	601
13	Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. <i>World Psychiatry</i> , 2015, 14, 119-136.	10.4	581
14	Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis. <i>JAMA Psychiatry</i> , 2018, 75, 555.	11.0	516
15	Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. <i>World Psychiatry</i> , 2016, 15, 166-174.	10.4	487
16	Relapse Prevention in Schizophrenia With New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized, Controlled Trials. <i>American Journal of Psychiatry</i> , 2003, 160, 1209-1222.	7.2	455
17	EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). <i>European Psychiatry</i> , 2018, 54, 124-144.	0.2	377
18	Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 957-965.	2.2	371

#	ARTICLE	IF	CITATIONS
19	National Trends in the Mental Health Care of Children, Adolescents, and Adults by Office-Based Physicians. <i>JAMA Psychiatry</i> , 2014, 71, 81.	11.0	368
20	Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2009, 35, 443-457.	4.3	360
21	Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. <i>World Psychiatry</i> , 2013, 12, 216-226.	10.4	356
22	Endocrine and Metabolic Adverse Effects of Psychotropic Medications in Children and Adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 771-791.	0.5	343
23	<p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 519-534.	2.2	339
24	Metabolic Syndrome and Metabolic Abnormalities in Bipolar Disorder: A Meta-Analysis of Prevalence Rates and Moderators. <i>American Journal of Psychiatry</i> , 2013, 170, 265-274.	7.2	336
25	Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. <i>Schizophrenia Bulletin</i> , 2014, 40, 192-213.	4.3	332
26	Tardive dyskinesia and new antipsychotics. <i>Current Opinion in Psychiatry</i> , 2008, 21, 151-156.	6.3	331
27	The Schizophrenia Prodrome Revisited: A Neurodevelopmental Perspective. <i>Schizophrenia Bulletin</i> , 2003, 29, 633-651.	4.3	327
28	Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders. <i>JAMA Psychiatry</i> , 2014, 71, 1350.	11.0	318
29	National Trends in the Office-Based Treatment of Children, Adolescents, and Adults With Antipsychotics. <i>Archives of General Psychiatry</i> , 2012, 69, 1247.	12.3	312
30	Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. <i>European Psychiatry</i> , 2011, 26, 144-158.	0.2	302
31	Single-dose infusion ketamine and non-ketamine <i>N</i> -methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. <i>Psychological Medicine</i> , 2016, 46, 1459-1472.	4.5	292
32	Prevention of Psychosis. <i>JAMA Psychiatry</i> , 2020, 77, 755.	11.0	287
33	Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 757-777.	2.0	286
34	Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. <i>Psychological Medicine</i> , 2012, 42, 125-147.	4.5	278
35	Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2008, 47, 9-20.	0.5	274
36	The Use of Long-Acting Injectable Antipsychotics in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1-24.	2.2	267

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1205-1218.	2.1	257
38	Antipsychotic drugs and obesity. <i>Trends in Molecular Medicine</i> , 2011, 17, 97-107.	6.7	256
39	Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. <i>Schizophrenia Research</i> , 2012, 138, 18-28.	2.0	255
40	Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions. <i>World Psychiatry</i> , 2013, 12, 155-164.	10.4	249
41	Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics. <i>JAMA Psychiatry</i> , 2019, 76, 1052.	11.0	243
42	20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). <i>World Psychiatry</i> , 2020, 19, 61-68.	10.4	232
43	Efficacy and Safety of Lumateperone for Treatment of Schizophrenia. <i>JAMA Psychiatry</i> , 2020, 77, 349.	11.0	226
44	Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 517-535.	1.3	221
45	A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. <i>World Psychiatry</i> , 2013, 12, 240-250.	10.4	220
46	Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. <i>Schizophrenia Research</i> , 2007, 89, 91-100.	2.0	219
47	Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 97-108.	4.5	216
48	From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. <i>European Psychiatry</i> , 2010, 25, S12-S21.	0.2	215
49	Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. <i>Schizophrenia Research</i> , 2004, 68, 37-48.	2.0	207
50	Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis. <i>Neuropsychopharmacology</i> , 2010, 35, 1520-1530.	5.4	206
51	Prediction of Functional Outcome in Individuals at Clinical High Risk for Psychosis. <i>JAMA Psychiatry</i> , 2013, 70, 1133.	11.0	202
52	The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. <i>NPJ Schizophrenia</i> , 2020, 6, 1.	3.6	193
53	Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. <i>JAMA Psychiatry</i> , 2019, 76, 499.	11.0	191
54	Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics. <i>JAMA Psychiatry</i> , 2016, 73, 247.	11.0	189

#	ARTICLE	IF	CITATIONS
55	Past and Present Progress in the Pharmacologic Treatment of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1115-1124.	2.2	188
56	What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. <i>World Psychiatry</i> , 2018, 17, 149-160.	10.4	188
57	Clinical predictors of therapeutic response to antipsychotics in schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2014, 16, 505-524.	3.7	186
58	Can Antidepressants Be Used to Treat the Schizophrenia Prodrome?. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 546-557.	2.2	185
59	Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. <i>European Neuropsychopharmacology</i> , 2009, 19, 629-635.	0.7	184
60	Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2010, 35, 1997-2004.	5.4	183
61	Preventive psychiatry: a blueprint for improving the mental health of young people. <i>World Psychiatry</i> , 2021, 20, 200-221.	10.4	183
62	Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. <i>Ageing Research Reviews</i> , 2017, 35, 63-73.	10.9	182
63	Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. <i>Bipolar Disorders</i> , 2010, 12, 116-141.	1.9	181
64	Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e264-e278.	2.2	179
65	Differentiation in the Preonset Phases of Schizophrenia and Mood Disorders: Evidence in Support of a Bipolar Mania Prodrome. <i>Schizophrenia Bulletin</i> , 2007, 33, 703-714.	4.3	175
66	Metabolic Syndrome and the Risk of Coronary Heart Disease in 367 Patients Treated With Second-Generation Antipsychotic Drugs. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 575-583.	2.2	175
67	Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. <i>British Journal of Psychiatry</i> , 2011, 199, 99-105.	2.8	169
68	Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. <i>European Neuropsychopharmacology</i> , 2011, 21, 621-645.	0.7	168
69	Adjunctive Use of Nonsteroidal Anti-inflammatory Drugs for Schizophrenia: A Meta-analytic Investigation of Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2013, 39, 1230-1241.	4.3	168
70	Research in people with psychosis risk syndrome: a review of the current evidence and future directions. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2010, 51, 390-431.	5.2	167
71	Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. <i>World Psychiatry</i> , 2020, 19, 214-232.	10.4	167
72	Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug-Induced Weight Gain. <i>Archives of General Psychiatry</i> , 2012, 69, 904.	12.3	165

#	ARTICLE	IF	CITATIONS
73	Impact of Neurocognition on Social and Role Functioning in Individuals at Clinical High Risk for Psychosis. <i>American Journal of Psychiatry</i> , 2011, 168, 806-813.	7.2	164
74	Inflammatory cytokines and anorexia nervosa: A meta-analysis of cross-sectional and longitudinal studies. <i>Psychoneuroendocrinology</i> , 2015, 51, 237-252.	2.7	164
75	Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2006, 15, 177-206.	1.9	163
76	Safety and tolerability of antipsychotic polypharmacy. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 527-542.	2.4	163
77	Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. <i>Schizophrenia Research</i> , 2012, 140, 159-168.	2.0	161
78	Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-“post studies. <i>Lancet Psychiatry</i> , 2021, 8, 387-404.	7.4	160
79	Early Prediction of Antipsychotic Response in Schizophrenia. <i>American Journal of Psychiatry</i> , 2003, 160, 2063-2065.	7.2	159
80	Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2015, 172, 870-880.	7.2	158
81	Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	157
82	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. <i>World Psychiatry</i> , 2017, 16, 77-89.	10.4	156
83	Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. <i>World Psychiatry</i> , 2022, 21, 248-271.	10.4	156
84	Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 675.	11.0	153
85	The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. <i>Bipolar Disorders</i> , 2017, 19, 524-543.	1.9	152
86	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015, 172, 617-629.	7.2	150
87	Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2016, 42, 1418-1437.	4.3	149
88	Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. <i>BMC Psychiatry</i> , 2005, 5, 26.	2.6	148
89	Weight Gain and Metabolic Effects of Mood Stabilizers and Antipsychotics in Pediatric Bipolar Disorder: A Systematic Review and Pooled Analysis of Short-Term Trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 687-700.	0.5	143
90	Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. <i>Bipolar Disorders</i> , 2008, 10, 788-797.	1.9	143

#	ARTICLE	IF	CITATIONS
91	Association of Antidepressant Use With Adverse Health Outcomes. <i>JAMA Psychiatry</i> , 2019, 76, 1241.	11.0	143
92	Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1–12.5 Years. <i>Schizophrenia Bulletin</i> , 2019, 45, 315-329.	4.3	141
93	Worldwide Differences in Regulations of Clozapine Use. <i>CNS Drugs</i> , 2016, 30, 149-161.	5.9	139
94	Inverse relationship between body mass index and mortality in older nursing home residents: a meta-analysis of 19,538 elderly subjects. <i>Obesity Reviews</i> , 2015, 16, 1001-1015.	6.5	138
95	Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. <i>Schizophrenia Bulletin</i> , 2018, 44, 603-619.	4.3	137
96	Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder. <i>CNS Drugs</i> , 2012, 26, 733-759.	5.9	136
97	Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. <i>Molecular Psychiatry</i> , 2013, 18, 53-66.	7.9	136
98	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 719.	11.0	135
99	A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic. <i>Journal of Medical Virology</i> , 2022, 94, 1935-1949.	5.0	134
100	Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. <i>CNS Spectrums</i> , 2014, 19, 35-53.	1.2	132
101	Alpha-2 Agonists for Attention-Deficit/Hyperactivity Disorder in Youth: A Systematic Review and Meta-Analysis of Monotherapy and Add-On Trials to Stimulant Therapy. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 153-173.	0.5	132
102	Efficacy and Safety of Atomoxetine in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Results From a Comprehensive Meta-Analysis and Metaregression. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 174-187.	0.5	131
103	What is good mental health? A scoping review. <i>European Neuropsychopharmacology</i> , 2020, 31, 33-46.	0.7	131
104	Suicidal ideation and suicide attempts in children and adolescents with bipolar disorder: a systematic review of prevalence and incidence rates, correlates, and targeted interventions. <i>Bipolar Disorders</i> , 2013, 15, 507-523.	1.9	129
105	The Bipolar Prodrome: Meta-Analysis of Symptom Prevalence Prior to Initial or Recurrent Mood Episodes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 543-555.	0.5	129
106	The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 303-318.	2.7	129
107	Psychosis Prevention: A Modified Clinical High Risk Perspective From the Recognition and Prevention (RAP) Program. <i>American Journal of Psychiatry</i> , 2015, 172, 986-994.	7.2	128
108	Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas. <i>World Psychiatry</i> , 2021, 20, 417-436.	10.4	127

#	ARTICLE	IF	CITATIONS
109	Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. <i>BMC Medicine</i> , 2016, 14, 189.	5.5	119
110	Analgesic Effects of Alcohol: A Systematic Review and Meta-Analysis of Controlled Experimental Studies in Healthy Participants. <i>Journal of Pain</i> , 2017, 18, 499-510.	1.4	119
111	The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good. <i>Danish Medical Journal</i> , 2013, 60, A4578.	0.5	118
112	Treatment of Maladaptive Aggression in Youth: CERT Guidelines II. Treatments and Ongoing Management. <i>Pediatrics</i> , 2012, 129, e1577-e1586.	2.1	117
113	Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. <i>World Psychiatry</i> , 2018, 17, 330-340.	10.4	117
114	Is Pain Perception Altered in People With Depression? A Systematic Review and Meta-Analysis of Experimental Pain Research. <i>Journal of Pain</i> , 2016, 17, 1257-1272.	1.4	114
115	Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4717839 people. <i>Lancet Psychiatry</i> , 2020, 7, 52-63.	7.4	109
116	Developments in Pediatric Psychopharmacology. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 655-670.	2.2	109
117	Early identification and high-risk strategies for bipolar disorder. <i>Bipolar Disorders</i> , 2007, 9, 324-338.	1.9	108
118	Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. <i>Psychological Medicine</i> , 2016, 46, 623-635.	4.5	108
119	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	3.3	107
120	A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. <i>Psychological Medicine</i> , 2015, 45, 299-317.	4.5	105
121	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1348-1357.	2.2	105
122	Clinical Characteristics and Predictors of Outcome of Schizophrenia-Spectrum Psychosis in Children and Adolescents: A Systematic Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 410-427.	1.3	104
123	Consensus statement on the use of clozapine during the COVID-19 pandemic. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 222-223.	2.4	102
124	Duration of Untreated Psychosis in Community Treatment Settings in the United States. <i>Psychiatric Services</i> , 2015, 66, 753-756.	2.0	100
125	A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. <i>Schizophrenia Bulletin</i> , 2015, 41, 1227-1236.	4.3	100
126	Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. <i>Schizophrenia Research</i> , 2010, 117, 68-74.	2.0	99

#	ARTICLE	IF	CITATIONS
127	Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. <i>Schizophrenia Research</i> , 2016, 176, 220-230.	2.0	97
128	Management of antipsychotic-related weight gain. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1175-1200.	2.8	95
129	Decreased pain sensitivity among people with schizophrenia. <i>Pain</i> , 2015, 156, 2121-2131.	4.2	95
130	Annual Research Review: Prevention of psychosis in adolescents – systematic review and meta-analysis of advances in detection, prognosis and intervention. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2021, 62, 657-673.	5.2	95
131	Quantifying Clinical Relevance in the Treatment of Schizophrenia. <i>Clinical Therapeutics</i> , 2011, 33, B16-B39.	2.5	94
132	Bone mineral density, osteoporosis, and fractures among people with eating disorders: a systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2016, 133, 341-351.	4.5	94
133	Antipsychotic Polypharmacy. <i>Psychiatric Clinics of North America</i> , 2012, 35, 661-681.	1.3	93
134	Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. <i>World Psychiatry</i> , 2019, 18, 208-224.	10.4	93
135	Osteoporosis and fracture risk in people with schizophrenia. <i>Current Opinion in Psychiatry</i> , 2012, 25, 415-429.	6.3	91
136	Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode. <i>Bipolar Disorders</i> , 2014, 16, 478-492.	1.9	91
137	Risk constellations prior to the development of bipolar disorders: Rationale of a new risk assessment tool. <i>Journal of Affective Disorders</i> , 2012, 136, 1000-1010.	4.1	90
138	Cost-Effective Screening for the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotic Medications. <i>American Journal of Psychiatry</i> , 2005, 162, 1217-1221.	7.2	89
139	Clinical risk factors for the development of tardive dyskinesia. <i>Journal of the Neurological Sciences</i> , 2018, 389, 21-27.	0.6	89
140	Digital Parent Training for Children with Disruptive Behaviors: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 740-749.	1.3	88
141	One-Year Incidence Rates of Tardive Dyskinesia in Children and Adolescents Treated with Second-Generation Antipsychotics: A Systematic Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 647-655.	1.3	87
142	Findings of a U.S. National Cardiometabolic Screening Program Among 10,084 Psychiatric Outpatients. <i>Psychiatric Services</i> , 2010, 61, 892-898.	2.0	87
143	Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. <i>CNS Spectrums</i> , 2019, 24, 38-69.	1.2	87
144	Pharmacologic treatment of schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2010, 12, 345-357.	3.7	86

#	ARTICLE	IF	CITATIONS
145	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	86
146	Pharmacogenetics of antipsychotic-induced weight gain. <i>Psychopharmacology</i> , 2004, 174, 477-89.	3.1	83
147	Treatment of adolescents with early-onset schizophrenia spectrum disorders. <i>Current Opinion in Psychiatry</i> , 2013, 26, 219-230.	6.3	82
148	Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. <i>World Psychiatry</i> , 2015, 14, 56-63.	10.4	82
149	Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study. <i>American Journal of Psychiatry</i> , 2015, 172, 237-248.	7.2	80
150	The pharmacological management of metabolic syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 397-410.	3.1	80
151	Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. <i>International Review of Psychiatry</i> , 2008, 20, 195-201.	2.8	78
152	Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior. <i>Schizophrenia Research</i> , 2011, 131, 58-62.	2.0	78
153	The Bipolar Prodrome Symptom Interview and Scale—Prospective (<scp>BPSS</scp>): description and validation in a psychiatric sample and healthy controls. <i>Bipolar Disorders</i> , 2014, 16, 505-522.	1.9	77
154	Second-Generation Antipsychotic Use in Children and Adolescents: A Six-Month Prospective Cohort Study in Drug-Naïve Patients. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 1179-1190.e4.	0.5	76
155	Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. <i>World Psychiatry</i> , 2021, 20, 244-275.	10.4	76
156	Predictors of Clozapine Response in Patients With Treatment-Refractory Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 678-683.	1.4	75
157	The Role of Clozapine in Treatment-Resistant Schizophrenia. <i>JAMA Psychiatry</i> , 2016, 73, 187.	11.0	72
158	Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. <i>American Journal of Psychiatry</i> , 2020, 177, 1168-1178.	7.2	72
159	ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. <i>Journal of Psychiatric Research</i> , 2018, 105, 23-32.	3.1	71
160	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 720-740.	1.9	71
161	The prevalence and moderators of clinical pain in people with schizophrenia: A systematic review and large scale meta-analysis. <i>Schizophrenia Research</i> , 2014, 160, 1-8.	2.0	70
162	Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. <i>Journal of Psychiatric Research</i> , 2016, 81, 95-101.	3.1	70

#	ARTICLE	IF	CITATIONS
163	10-Year trends in the treatment and outcomes of patients with first-episode schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2010, 122, 356-366.	4.5	69
164	Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 293-302.	4.4	69
165	Sudden unexpected death in schizophrenia: Autopsy findings in psychiatric inpatients. <i>Schizophrenia Research</i> , 2014, 155, 72-76.	2.0	68
166	Poor Sleep Is Related to Lower Emotional Competence Among Adolescents. <i>Behavioral Sleep Medicine</i> , 2016, 14, 602-614.	2.1	68
167	Metformin addition vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. <i>World Psychiatry</i> , 2020, 19, 69-80.	10.4	68
168	The Assessment of "Prodromal Schizophrenia": Unresolved Issues and Future Directions. <i>Schizophrenia Bulletin</i> , 2003, 29, 717-728.	4.3	67
169	Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. <i>CNS Drugs</i> , 2021, 35, 39-59.	5.9	67
170	The Effects of Valbenazine in Participants with Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1344-1350.	2.2	67
171	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 136, 104608.	6.1	67
172	Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 749-761.	7.4	66
173	The association between smoking prevalence and eating disorders: a systematic review and meta-analysis. <i>Addiction</i> , 2016, 111, 1914-1922.	3.3	65
174	Investigational drugs in recent clinical trials for treatment-resistant depression. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 593-609.	2.8	65
175	Demographic and clinical correlates of substance use disorders in first episode psychosis. <i>Schizophrenia Research</i> , 2018, 194, 4-12.	2.0	65
176	Balancing Efficacy and Safety in Treatment with Antipsychotics. <i>CNS Spectrums</i> , 2007, 12, 12-20.	1.2	64
177	Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia. <i>JAMA Psychiatry</i> , 2021, 78, 510.	11.0	63
178	Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. <i>Bipolar Disorders</i> , 2013, 15, 138-149.	1.9	62
179	Corrected QT Changes During Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 25-36.	0.5	62
180	A Prospective Study of Hyperprolactinemia in Children and Adolescents Treated with Atypical Antipsychotic Agents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 350-358.	1.3	60

#	ARTICLE	IF	CITATIONS
181	Lifestyle Interventions for Weight Management in People with Serious Mental Illness: A Systematic Review with Meta-Analysis, Trial Sequential Analysis, and Meta-Regression Analysis Exploring the Mediators and Moderators of Treatment Effects. <i>Psychotherapy and Psychosomatics</i> , 2019, 88, 350-362.	8.8	60
182	Sudden Deaths in Psychiatric Patients. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 936-941.	2.2	60
183	Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. <i>CNS Spectrums</i> , 2017, 22, 415-426.	1.2	59
184	Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 187-205.	4.5	59
185	Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies. <i>Acta Psychiatrica Scandinavica</i> , 2019, 140, 227-243.	4.5	59
186	Prevalence of aggression in hospitalized patients with schizophrenia in China: A meta-analysis. <i>Asia-Pacific Psychiatry</i> , 2016, 8, 60-69.	2.2	58
187	Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia – Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. <i>Schizophrenia Bulletin</i> , 2020, 46, 1459-1470.	4.3	58
188	Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1136-1147.	2.2	58
189	Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 456-468.e4.	0.5	57
190	Comparing clinical and neurocognitive features of the schizophrenia prodrome to the bipolar prodrome. <i>Schizophrenia Research</i> , 2010, 123, 59-63.	2.0	56
191	Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. <i>European Neuropsychopharmacology</i> , 2015, 25, 1513-1531.	0.7	56
192	Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2020, 41, 28-39.	0.7	56
193	Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 16-23.	2.2	56
194	Cost of antipsychotic polypharmacy in the treatment of schizophrenia. <i>BMC Psychiatry</i> , 2008, 8, 19.	2.6	54
195	Markers of inflammation in schizophrenia: association vs. causation. <i>World Psychiatry</i> , 2014, 13, 189-192.	10.4	54
196	A Severity-Based Clinical Staging Model for the Psychosis Prodrome: Longitudinal Findings From the New York Recognition and Prevention Program. <i>Schizophrenia Bulletin</i> , 2017, 43, 64-74.	4.3	54
197	Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis. <i>American Journal of Psychiatry</i> , 2021, 178, 424-436.	7.2	54
198	Management of Patients With Severe Mental Illness During the Coronavirus Disease 2019 Pandemic. <i>JAMA Psychiatry</i> , 2020, 77, 977.	11.0	53

#	ARTICLE	IF	CITATIONS
199	Oxidative stress parameters and antioxidants in patients with bipolar disorder: Results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls. <i>Bipolar Disorders</i> , 2021, 23, 117-129.	1.9	53
200	Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. <i>Psychoneuroendocrinology</i> , 2015, 58, 130-140.	2.7	52
201	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. <i>BMC Medicine</i> , 2020, 18, 215.	5.5	52
202	Frequency and Correlates of Inappropriate Pediatric Psychiatric Emergency Room Visits. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1164-1177.	2.2	52
203	The Significance of At-Risk or Prodromal Symptoms for Bipolar I Disorder in Children and Adolescents. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 22-31.	1.9	51
204	Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 385-398.	4.5	51
205	Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1215-1238.	4.3	51
206	Predictors of Remission, Schizophrenia, and Bipolar Disorder in Adolescents with Brief Psychotic Disorder or Psychotic Disorder Not Otherwise Specified Considered At Very High Risk for Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 475-490.	1.3	50
207	Lack of Effect of Stimulant Combination with Second-Generation Antipsychotics on Weight Gain, Metabolic Changes, Prolactin Levels, and Sedation in Youth with Clinically Relevant Aggression or Oppositionality. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 563-573.	1.3	50
208	Disparities in Screening and Treatment of Cardiovascular Diseases in Patients With Mental Disorders Across the World: Systematic Review and Meta-Analysis of 47 Observational Studies. <i>American Journal of Psychiatry</i> , 2021, 178, 793-803.	7.2	50
209	Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. <i>Lancet Psychiatry</i> , 2021, 8, 883-891.	7.4	50
210	Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. <i>Schizophrenia Research</i> , 2016, 174, 93-98.	2.0	49
211	Antidepressants for cognitive impairment in schizophrenia – A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2014, 159, 385-394.	2.0	48
212	Rapid clozapine titration in treatment-refractory bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 166, 168-172.	4.1	48
213	Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. <i>NPJ Schizophrenia</i> , 2022, 8, 5.	3.6	48
214	Ambiguous findings concerning potential advantages of depot antipsychotics. <i>Current Opinion in Psychiatry</i> , 2015, 28, 216-221.	6.3	47
215	Cognitive functioning in individuals at ultra-high risk for psychosis, first-degree relatives of patients with psychosis and patients with first-episode schizophrenia. <i>Schizophrenia Research</i> , 2016, 174, 71-76.	2.0	47
216	Symptomatic and functional remission of subjects at clinical high risk for psychosis: A 2-year naturalistic observational study. <i>Schizophrenia Research</i> , 2014, 156, 266-271.	2.0	46

#	ARTICLE	IF	CITATIONS
217	Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. <i>American Journal of Psychiatry</i> , 2018, 175, 169-179.	7.2	46
218	Incidence of Tardive Dyskinesia with Risperidone or Olanzapine in the Elderly: Results from a 2-Year, Prospective Study in Antipsychotic-Naïve Patients. <i>Neuropsychopharmacology</i> , 2011, 36, 1738-1746.	5.4	45
219	Frequency, Characteristics and Management of Adolescent Inpatient Aggression. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 271-281.	1.3	45
220	Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1095-1105.	2.1	45
221	Perfectionism related to self-reported insomnia severity, but not when controlled for stress and emotion regulation. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 263.	2.2	45
222	Technology-Assisted Parent Training Programs for Children and Adolescents With Disruptive Behaviors. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e957-e969.	2.2	45
223	Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. <i>Journal of Clinical Psychiatry</i> , 2008, 69 Suppl 4, 26-36.	2.2	45
224	Emerging drugs for schizophrenia: an update. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 511-531.	2.4	44
225	Comparative Effectiveness of Risperidone Long-Acting Injectable vs First-Generation Antipsychotic Long-Acting Injectables in Schizophrenia: Results From a Nationwide, Retrospective Inception Cohort Study. <i>Schizophrenia Bulletin</i> , 2015, 41, 627-636.	4.3	44
226	Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. <i>Schizophrenia Research</i> , 2016, 174, 82-92.	2.0	44
227	Oral and long-acting antipsychotics for relapse prevention in schizophrenia spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. <i>World Psychiatry</i> , 2022, 21, 295-307.	10.4	44
228	Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1665-1675.	3.8	43
229	National Patterns of Commonly Prescribed Psychotropic Medications to Young People. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 158-165.	1.3	43
230	Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1616-1627.	2.2	43
231	Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2022, 19, e1003960.	8.4	43
232	A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. <i>Schizophrenia Research</i> , 2018, 195, 245-251.	2.0	42
233	Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: Findings of the third national survey on use of psychotropic medications in China. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 129-136.	2.3	40
234	ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 601-614.	2.8	40

#	ARTICLE	IF	CITATIONS
235	Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. <i>Lancet Psychiatry</i> , 2017, 4, 605-618.	7.4	40
236	Side Effects of Second-Generation Antipsychotics: The Experiences, Views and Monitoring Practices of Australian Child Psychiatrists. <i>Australasian Psychiatry</i> , 2008, 16, 253-262.	0.7	39
237	Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics. <i>Drugs</i> , 2020, 80, 1763-1781.	10.9	39
238	Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. <i>NPJ Schizophrenia</i> , 2021, 7, 63.	3.6	39
239	Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e933-e939.	2.2	38
240	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). <i>European Neuropsychopharmacology</i> , 2019, 29, 1301-1311.	0.7	38
241	Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. <i>Dialogues in Clinical Neuroscience</i> , 2011, 13, 155-172.	3.7	38
242	Systematic review and guide to management of core and psychiatric symptoms in youth with autism. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 379-400.	4.5	37
243	Body Mass Index Identified as an Independent Predictor of Psychiatric Readmission. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e573-e577.	2.2	37
244	Adherence to Guidelines for Glucose Assessment in Starting Second-Generation Antipsychotics. <i>Pediatrics</i> , 2014, 134, e1308-e1314.	2.1	36
245	Smoking in male patients with schizophrenia in China: A meta-analysis. <i>Drug and Alcohol Dependence</i> , 2016, 162, 146-153.	3.2	36
246	Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet Psychiatry</i> , 2021, 8, 471-486.	7.4	36
247	Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1035-e1046.	2.2	36
248	Prospective Study of Adolescents with Subsyndromal Psychosis: Characteristics and Outcome. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005, 15, 418-433.	1.3	35
249	Pharmacoepidemiology of Antipsychotic Use in Youth with ADHD: Trends and Clinical Implications. <i>Current Psychiatry Reports</i> , 2013, 15, 382.	4.5	35
250	Associations Among Obesity, Acute Weight Gain, and Response to Treatment with Olanzapine in Adolescent Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 522-530.	1.3	35
251	The impact of psychosis on the course of cognition: a prospective, nested case-control study in individuals at clinical high-risk for psychosis. <i>Psychological Medicine</i> , 2015, 45, 3341-3354.	4.5	35
252	Child and Adolescent Psychiatrists' Reported Monitoring Behaviors for Second-Generation Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 351-361.	1.3	35

#	ARTICLE	IF	CITATIONS
253	Pain perception in Parkinson's disease: A systematic review and meta-analysis of experimental studies. <i>Ageing Research Reviews</i> , 2017, 35, 74-86.	10.9	35
254	Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists. <i>BMC Psychiatry</i> , 2019, 19, 362.	2.6	35
255	Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics). <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	35
256	Management of physical health in patients with schizophrenia: practical recommendations. <i>European Psychiatry</i> , 2010, 25, S41-S45.	0.2	34
257	The bipolar disorder prodrome revisited: Is there a symptomatic pattern?. <i>Journal of Affective Disorders</i> , 2013, 151, 551-560.	4.1	34
258	National Trends in Second-Generation Antipsychotic Augmentation for Nonpsychotic Depression. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 490-497.	2.2	34
259	Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 1611-1620.	4.3	33
260	Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e746-e756.	2.2	33
261	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). <i>Journal of Affective Disorders</i> , 2022, 299, 367-376.	4.1	33
262	Diagnosis and treatment in the early illness phase of bipolar disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 50-54.	3.2	32
263	Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 718-727.e3.	0.5	32
264	Antipsychotic Use in Youth Without Psychosis. <i>JAMA Psychiatry</i> , 2015, 72, 859.	11.0	32
265	How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 189-202.	1.7	32
266	Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. <i>CNS Drugs</i> , 2021, 35, 1189-1205.	5.9	32
267	Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis. <i>Psychoneuroendocrinology</i> , 2016, 72, 1-10.	2.7	31
268	Digital Trajectories to Care in First-Episode Psychosis. <i>Psychiatric Services</i> , 2018, 69, 1259-1263.	2.0	31
269	The role of meta-analyses and umbrella reviews in assessing the harms of psychotropic medications: beyond qualitative synthesis. <i>Epidemiology and Psychiatric Sciences</i> , 2018, 27, 537-542.	3.9	31
270	Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study. <i>Schizophrenia Research</i> , 2020, 215, 408-415.	2.0	31

#	ARTICLE	IF	CITATIONS
271	Medical management of eating disorders: an update. <i>Current Opinion in Psychiatry</i> , 2020, 33, 542-553.	6.3	31
272	Real-Life Switching Strategies With Second-Generation Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 160-161.	2.2	31
273	CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 186-192.	1.4	30
274	Early Nonresponse Determined by the Clinical Global Impressions Scale Predicts Poorer Outcomes in Youth with Schizophrenia Spectrum Disorders Naturalistically Treated with Second-Generation Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 665-675.	1.3	30
275	Use of electroconvulsive therapy for Asian patients with schizophrenia (2001â€“2009): Trends and correlates. <i>Psychiatry and Clinical Neurosciences</i> , 2015, 69, 489-496.	1.8	30
276	One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 26-36.	4.5	30
277	Acute and Long-Term Adverse Effects of Antipsychotics. <i>CNS Spectrums</i> , 2007, 12, 10-14.	1.2	29
278	Obesity and coronary risk in patients treated with second-generation antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 417-423.	3.2	29
279	Psychotherapeutic interventions in individuals at risk of developing bipolar disorder: a systematic review. <i>Microbial Biotechnology</i> , 2014, 8, 3-11.	1.7	29
280	Glutamatergic agents for schizophrenia: current evidence and perspectives. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 335-352.	3.1	29
281	Do antipsychotics increase diabetes risk in children and adolescents?. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 219-241.	2.4	29
282	Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 591-612.	2.4	29
283	Psychological well-being and mental health recovery in the NIMH RAISE early treatment program. <i>Schizophrenia Research</i> , 2017, 185, 167-172.	2.0	29
284	Risk factors of postpartum depression and depressive symptoms: umbrella review of current evidence from systematic reviews and meta-analyses of observational studies. <i>British Journal of Psychiatry</i> , 2022, 221, 591-602.	2.8	29
285	Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review. <i>Molecular Psychiatry</i> , 2022, 27, 3510-3519.	7.9	29
286	Antipsychotic Drug Administration Does Not Correlate with Prolonged Rate-Corrected QT Interval in Children and Adolescents: Results from a Nested Caseâ€“Control Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 365-368.	1.3	28
287	Antipsychotic polypharmacy: A Japanese survey of prescribers' attitudes and rationales. <i>Psychiatry Research</i> , 2013, 209, 406-411.	3.3	28
288	Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. <i>CNS Spectrums</i> , 2016, 21, 393-402.	1.2	28

#	ARTICLE	IF	CITATIONS
289	<p></p>Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia</p><p></p>Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1365-1379.	2.2	28
290	Effectiveness of Transdiagnostic Cognitive-Behavioral Psychotherapy Compared With Management as Usual for Youth With Common Mental Health Problems. JAMA Psychiatry, 2021, 78, 250.	11.0	28
291	Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study. European Neuropsychopharmacology, 2015, 25, 1669-1676.	0.7	27
292	Clinical Characteristics of Inpatients with Childhood vs. Adolescent Anorexia Nervosa. Nutrients, 2019, 11, 2593.	4.1	27
293	A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica, 2021, 144, 329-341.	4.5	27
294	Child and Adolescent Psychiatrists' Attitudes and Practices Prescribing Second Generation Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 90-93.	1.3	26
295	Frequency of Involuntary Admissions and Its Associations With Demographic and Clinical Characteristics in China. Archives of Psychiatric Nursing, 2014, 28, 272-276.	1.4	26
296	Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opinion on Pharmacotherapy, 2016, 17, 921-936.	1.8	26
297	Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. European Child and Adolescent Psychiatry, 2016, 25, 1091-1102.	4.7	26
298	Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1463-1474.	2.2	26
299	Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. Psychological Medicine, 2020, 50, 1356-1367.	4.5	26
300	Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2021, 47, 948-958.	4.3	26
301	Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. Schizophrenia Bulletin, 2022, 48, 166-175.	4.3	26
302	Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Frontiers in Psychiatry, 2012, 3, 62.	2.6	25
303	Early specific cognitive-behavioural psychotherapy in subjects at high risk for bipolar disorders: study protocol for a randomised controlled trial. Trials, 2014, 15, 161.	1.6	25
304	Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia. International Clinical Psychopharmacology, 2015, 30, 272-281.	1.7	25
305	Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis. EClinicalMedicine, 2021, 36, 100909.	7.1	25
306	Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study. Lancet Psychiatry, the, 2022, 9, 271-279.	7.4	25

#	ARTICLE	IF	CITATIONS
307	Adaptation of a peer based online emotional support program as an adjunct to treatment for people with schizophrenia-spectrum disorders. <i>Internet Interventions</i> , 2016, 4, 35-42.	2.7	24
308	An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. <i>Journal of Psychopharmacology</i> , 2019, 33, 1227-1236.	4.0	24
309	Patches. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	24
310	Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. <i>Schizophrenia Bulletin</i> , 2021, 47, 1621-1630.	4.3	24
311	QT Interval Duration and Dispersion in Children and Adolescents Treated With Ziprasidone. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 854-860.	2.2	24
312	Suicidality in Childhood and Adolescence. <i>Deutsches A&#x0308;rzteblatt International</i> , 2020, 117, 261-267.	0.9	24
313	Outcomes of SARS survivors in China: not only physical and psychiatric co-morbidities. <i>East Asian Archives of Psychiatry</i> , 2014, 24, 37-8.	0.4	24
314	Experts' Recommendations for Treating Maladaptive Aggression in Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 505-515.	1.3	23
315	Early Antipsychotic Response to Aripiprazole in Adolescents With Schizophrenia: Predictive Value for Clinical Outcomes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 689-698.e3.	0.5	23
316	Characteristics, symptomatology and naturalistic treatment in individuals at-risk for bipolar disorders: Baseline results in the first 180 help-seeking individuals assessed at the dresden high-risk project. <i>Journal of Affective Disorders</i> , 2014, 152-154, 427-433.	4.1	23
317	Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms. <i>Psychological Medicine</i> , 2016, 46, 1069-1078.	4.5	23
318	Health Technology Intervention After Hospitalization for Schizophrenia: Service Utilization and User Satisfaction. <i>Psychiatric Services</i> , 2016, 67, 1035-1038.	2.0	23
319	Predictors of psychosis breakthrough during 24Âmonths of long-acting antipsychotic maintenance treatment in first episode schizophrenia. <i>Schizophrenia Research</i> , 2020, 225, 55-62.	2.0	23
320	Primary prevention of depression: An umbrella review of controlled interventions. <i>Journal of Affective Disorders</i> , 2021, 294, 957-970.	4.1	23
321	Risk of Diabetes in Children and Adolescents Exposed to Antipsychotics: A Nationwide 12-Year Case-Control Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 971-979.e6.	0.5	22
322	Real-World Effectiveness of Clozapine for Borderline Personality Disorder: Results From a 2-Year Mirror-Image Study. <i>Journal of Personality Disorders</i> , 2018, 32, 823-837.	1.4	22
323	Comorbidity of chronic somatic diseases in patients with psychotic disorders and their influence on 4-year outcomes of integrated care treatment (ACCESS II study). <i>Schizophrenia Research</i> , 2018, 193, 377-383.	2.0	22
324	Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. <i>BMC Psychiatry</i> , 2018, 18, 365.	2.6	22

#	ARTICLE	IF	CITATIONS
325	The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2022, 299, 393-407.	4.1	22
326	Low Hemoglobin Levels and Risk of Developing Depression in the Elderly. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1549-e1556.	2.2	22
327	AACAP 2006 Research Forum "Advancing Research in Early-Onset Bipolar Disorder: Barriers and Suggestions. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 3-12.	1.3	21
328	The QTc interval and its dispersion in patients receiving two atypical antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 23-27.	3.2	21
329	Rational Use of Generic Psychotropic Drugs. <i>CNS Drugs</i> , 2013, 27, 353-365.	5.9	21
330	Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. <i>Schizophrenia Research</i> , 2013, 143, 358-362.	2.0	21
331	Temperament and prodromal symptoms prior to first manic/hypomanic episodes: Results from a pilot study. <i>Journal of Affective Disorders</i> , 2015, 173, 39-44.	4.1	21
332	Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 784-792.	0.5	21
333	Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1475-1492.	2.2	21
334	Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532094270.	2.7	21
335	Mortality After the First Diagnosis of Schizophrenia-Spectrum Disorders: A Population-based Retrospective Cohort Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 864-874.	4.3	21
336	Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data. <i>Schizophrenia Bulletin</i> , 2022, 48, 296-306.	4.3	21
337	A systematic meta-analysis of the association of Neuregulin 1 (NRG1), d-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia. <i>Journal of Neural Transmission</i> , 2018, 125, 89-102.	2.8	21
338	Differential Risk of Increasing Psychotropic Polypharmacy Use in Children Diagnosed With ADHD as Preschoolers. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e744-e781.	2.2	21
339	Using Long-acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	21
340	Metabolic Side Effects of Second-Generation Antipsychotics in Children and Adolescents: A Different Story?. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1331-1332.	2.2	21
341	Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed?. <i>Acta Psychiatrica Scandinavica</i> , 2010, 122, 341-344.	4.5	20
342	BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis. <i>Schizophrenia Research</i> , 2014, 152, 365-372.	2.0	20

#	ARTICLE	IF	CITATIONS
343	Suicidality and hospitalization as cause and outcome of pediatric psychiatric emergency room visits. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 797-814.	4.7	20
344	Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 458-470.	1.3	20
345	Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 1-14.	2.7	20
346	Validation study of the early onset schizophrenia diagnosis in the Danish Psychiatric Central Research Register. <i>European Child and Adolescent Psychiatry</i> , 2018, 27, 965-975.	4.7	20
347	Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. <i>Neuropsychiatric Disease and Treatment</i> . 2019. Volume 15. 2537-2550.	2.2	20
348	Network analysis of the relationship between depressive symptoms, demographics, nutrition, quality of life and medical condition factors in the Osteoarthritis Initiative database cohort of elderly North-American adults with or at risk for osteoarthritis. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e14.	3.9	20
349	Frequency and Correlates of DSM-5 Attenuated Psychosis Syndrome in a Sample of Adolescent Inpatients With Nonpsychotic Psychiatric Disorders. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1449-e1458.	2.2	20
350	Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. <i>European Psychiatry</i> , 2011, 26, 3-16.	0.2	19
351	Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2013, 7, 31.	2.5	19
352	Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001-2009). <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 359-366.	2.7	19
353	Critical Issues on the Use of Network Meta-analysis in Psychiatry. <i>Harvard Review of Psychiatry</i> , 2014, 22, 367-372.	2.1	19
354	Clinical characteristics and influence of childhood trauma on the prodrome of bipolar disorder. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 280-288.	1.7	19
355	Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1181-1199.	2.4	19
356	Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1587-1608.	2.4	19
357	Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia. <i>Epidemiology and Psychiatric Sciences</i> , 2016, 25, 9-17.	3.9	19
358	The role of genetic variation of human metabolism for BMI, mental traits and mental disorders. <i>Molecular Metabolism</i> , 2018, 12, 1-11.	6.5	19
359	Practice-Based Evidence and Clinical Guidance to Support Accelerated Re-Nutrition of Patients With Anorexia Nervosa. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 555-561.	0.5	19
360	Antipsychotic Polypharmacy, Part 1: Shotgun Approach or Targeted Cotreatment?. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 674-675.	2.2	19

#	ARTICLE	IF	CITATIONS
361	First-Episode Psychosis: A Window of Opportunity for Best Practices. <i>CNS Spectrums</i> , 2007, 12, 1-16.	1.2	18
362	Differences in Body Mass Index (BMI)-Scores and Weight Status in a Dutch Pediatric Psychiatric Population With and Without Use of Second-Generation Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2012, 22, 166-173.	1.3	18
363	Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 229-241.	2.6	18
364	Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 1485-1496.	4.7	18
365	Is Transcultural Psychiatry Possible?. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2167.	7.4	18
366	Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. <i>Movement Disorders</i> , 2019, 34, 1203-1209.	3.9	18
367	Improving early recognition and intervention in people at increased risk for the development of bipolar disorder: study protocol of a prospective-longitudinal, naturalistic cohort study (Early-BipoLife). <i>International Journal of Bipolar Disorders</i> , 2020, 8, 22.	2.2	18
368	Treatment Models and Designs for Intervention Research During the Psychotic Prodrome. <i>Schizophrenia Bulletin</i> , 2003, 29, 747-756.	4.3	17
369	Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: Missed targets and lost opportunities. <i>Schizophrenia Research</i> , 2007, 92, 103-107.	2.0	17
370	Antipsychotic Polypharmacy in a Treatment-Refractory Schizophrenia Population Receiving Adjunctive Treatment With Electroconvulsive Therapy. <i>Journal of ECT</i> , 2013, 29, 271-276.	0.6	17
371	Diabetes Risk Potentially Underestimated in Youth and Children Receiving Antipsychotics. <i>JAMA Psychiatry</i> , 2014, 71, 209.	11.0	17
372	Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002-2012). <i>Schizophrenia Research</i> , 2015, 168, 523-529.	2.0	17
373	Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 570-576.	1.4	17
374	Bipolar Prodrome Symptom Scale - Abbreviated Screen for Patients: Description and validation. <i>Journal of Affective Disorders</i> , 2019, 249, 357-365.	4.1	17
375	Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. <i>CNS Spectrums</i> , 2019, 24, 479-495.	1.2	17
376	Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. <i>CNS Spectrums</i> , 2019, 24, 354-370.	1.2	17
377	Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12-43 years. <i>Psychological Medicine</i> , 2021, 51, 1570-1580.	4.5	17
378	Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use. <i>Schizophrenia Bulletin</i> , 2020, 46, 1547-1557.	4.3	17

#	ARTICLE	IF	CITATIONS
379	Outcomes of an Accelerated Inpatient Refeeding Protocol in 103 Extremely Underweight Adults with Anorexia Nervosa at a Specialized Clinic in Prien, Germany. <i>Journal of Clinical Medicine</i> , 2020, 9, 1535.	2.4	17
380	Self-Reported and Interviewer-Rated Oral Health in Patients With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. <i>Perspectives in Psychiatric Care</i> , 2016, 52, 4-11.	1.9	16
381	Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. <i>Journal of Affective Disorders</i> , 2016, 197, 268-280.	4.1	16
382	Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits. <i>Frontiers in Psychiatry</i> , 2017, 8, 292.	2.6	16
383	Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2019, 58, 1062-1078.	0.5	16
384	Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019. <i>Current Psychiatry Reports</i> , 2019, 21, 124.	4.5	16
385	Association between mental disorders and somatic conditions: protocol for an umbrella review. <i>Evidence-Based Mental Health</i> , 2020, 23, 135-139.	4.5	16
386	The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Perspectives. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 376-380.	1.3	16
387	A symptom combination predicting treatment-resistant schizophrenia – A strategy for real-world clinical practice. <i>Schizophrenia Research</i> , 2020, 218, 195-200.	2.0	16
388	Safety and tolerability of lumateperone 42Âmg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. <i>Schizophrenia Research</i> , 2021, 228, 198-205.	2.0	16
389	What Are We Looking for in New Antipsychotics?. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 9-13.	2.2	16
390	Antipsychotic Polypharmacy in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	16
391	Elevated Cardiovascular Risk in Patients With Bipolar Disorder: When Does It Start and Where Does It Lead?. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1948-1952.	2.2	16
392	Using Patient-Centered Assessment in Schizophrenia Care. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	16
393	Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. <i>Psychopharmacology Bulletin</i> , 2017, 47, 53-60.	0.0	16
394	Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	15
395	High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. <i>CNS Spectrums</i> , 2019, 24, 441-452.	1.2	15
396	Metabolic Monitoring Rates of Youth Treated with Second-Generation Antipsychotics in Usual Care: Results of a Large US National Commercial Health Plan. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 119-122.	1.3	15

#	ARTICLE	IF	CITATIONS
397	Longitudinal Course of Depressive, Anxiety, and Posttraumatic Stress Disorder Symptoms After Heart Surgery: A Meta-Analysis of 94 Studies. <i>Psychosomatic Medicine</i> , 2021, 83, 85-93.	2.0	15
398	Appraising the effectiveness of electrical and magnetic brain stimulation techniques in acute major depressive episodes: an umbrella review of meta-analyses of randomized controlled trials. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 514-524.	1.7	15
399	Current Treatment Options and Emerging Agents for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	15
400	<i>Primum non nocere:</i> balancing the risks and benefits of prescribing psychotropic medications for youth with bipolar disorder. <i>Bipolar Disorders</i> , 2010, 12, 113-115.	1.9	14
401	Effectiveness of a Cognitive Behavioral Weight Management Intervention in Obese Patients With Psychotic Disorders Compared to Patients With Nonpsychotic Disorders or No Psychiatric Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 458-464.	1.4	14
402	Antipsychotics for acute schizophrenia: making choices. <i>Lancet, The</i> , 2013, 382, 919-920.	13.7	14
403	Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. <i>CNS Spectrums</i> , 2016, 21, 466-477.	1.2	14
404	Leptin and Physical Activity in Adult Patients with Anorexia Nervosa: Failure to Demonstrate a Simple Linear Association. <i>Nutrients</i> , 2017, 9, 1210.	4.1	14
405	Ranking Antipsychotics for Efficacy and Safety in Schizophrenia. <i>JAMA Psychiatry</i> , 2020, 77, 225.	11.0	14
406	Incontinence and constipation in adolescent patients with anorexia nervosaâ€”Results of a multicenter study from a German webâ€”based registry for children and adolescents with anorexia nervosa. <i>International Journal of Eating Disorders</i> , 2020, 53, 219-228.	4.0	14
407	Efficacy of cognitiveâ€”behavioral group therapy in patients at risk for serious mental illness presenting with subthreshold bipolar symptoms: Results from a prespecified interim analysis of a multicenter, randomized, controlled study. <i>Bipolar Disorders</i> , 2020, 22, 517-529.	1.9	14
408	The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index. <i>BMC Psychiatry</i> , 2020, 20, 77.	2.6	14
409	Risk and protective factors for mental disorders with onset in childhood/adolescence: An umbrella review of published meta-analyses of observational longitudinal studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 120, 565-573.	6.1	14
410	Association of Low-Dose Quetiapine and Diabetes. <i>JAMA Network Open</i> , 2021, 4, e213209.	5.9	14
411	Prospective Memory Performance in Non-Psychotic First-Degree Relatives of Patients with Schizophrenia: A Controlled Study. <i>PLoS ONE</i> , 2014, 9, e111562.	2.5	14
412	Schizophrenia: Mechanism of Action of Current and Novel Treatments. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 347-348.	2.2	14
413	Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. <i>Psychopharmacology Bulletin</i> , 2017, 47, 69-76.	0.0	14
414	Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice. <i>Pharmacopsychiatry</i> , 2022, 55, 255-265.	3.3	14

#	ARTICLE	IF	CITATIONS
415	Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 808002.	2.6	14
416	Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. <i>BMC Psychiatry</i> , 2015, 15, 271.	2.6	13
417	Impairment in Social Functioning differentiates youth meeting Ultra-High Risk for psychosis criteria from other mental health help-seekers: A validation of the Italian version of the Global Functioning: Social and Global Functioning: Role scales. <i>Psychiatry Research</i> , 2017, 253, 296-302.	3.3	13
418	Whatâ€™s in a Name? Moving to Neuroscience-Based Nomenclature in Pediatric Psychopharmacology. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, 719-721.	0.5	13
419	Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 41-49.	1.9	13
420	The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. <i>CNS Spectrums</i> , 2021, 26, 562-586.	1.2	13
421	Developing an International Standard Set of Patient-Reported Outcome Measures for Psychotic Disorders. <i>Psychiatric Services</i> , 2022, 73, 249-258.	2.0	13
422	Individuals at increased risk for development of bipolar disorder display structural alterations similar to people with manifest disease. <i>Translational Psychiatry</i> , 2021, 11, 485.	4.8	13
423	Antipsychotic Polypharmacy, Part 2: Why Use 2 Antipsychotics When 1 Is Not Good Enough?. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 860-861.	2.2	13
424	Therapeutic drug monitoring of sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder. <i>Comprehensive Psychiatry</i> , 2022, 115, 152301.	3.1	13
425	Prevalence of Nurses' Smoking Habits in Psychiatric and General Hospitals in China. <i>Archives of Psychiatric Nursing</i> , 2014, 28, 119-122.	1.4	12
426	Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study. <i>CNS Drugs</i> , 2016, 30, 997-1006.	5.9	12
427	Ï‰-3 Polyunsaturated Fatty Acids to Prevent Psychosis. <i>JAMA Psychiatry</i> , 2017, 74, 11.	11.0	12
428	Sex and body weight are major determinants of venlafaxine pharmacokinetics. <i>International Clinical Psychopharmacology</i> , 2018, 33, 322-329.	1.7	12
429	Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of cliniciansâ€™ choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. <i>CNS Spectrums</i> , 2019, 24, 507-517.	1.2	12
430	Age dependency of body mass index distribution in childhood and adolescent inpatients with anorexia nervosa with a focus on DSM-5 and ICD-11 weight criteria and severity specifiers. <i>European Child and Adolescent Psychiatry</i> , 2021, 30, 1081-1094.	4.7	12
431	Safety and Effectiveness of SEPâˆ™363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study. <i>CNS Spectrums</i> , 2021, 26, 148-149.	1.2	12
432	Editorial Perspective: Challenges of research focusing on child and adolescent mental health during the COVIDâ€“19 era: what studies are needed?. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2022, 63, 122-125.	5.2	12

#	ARTICLE	IF	CITATIONS
433	Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies. <i>European Neuropsychopharmacology</i> , 2020, 35, 1-11.	0.7	12
434	Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI). <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 68-72.	0.1	12
435	Switching among Antipsychotics in Everyday Clinical Practice: Focus on Ziprasidone. <i>Postgraduate Medicine</i> , 2011, 123, 135-159.	2.0	11
436	Recognition of bipolar disorder type I before the first manic episode: challenges and developments. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 795-807.	2.8	11
437	Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 901.	2.0	11
438	The Role of Objectively Measured, Altered Physical Activity Patterns for Body Mass Index Change during Inpatient Treatment in Female Patients with Anorexia Nervosa. <i>Journal of Clinical Medicine</i> , 2018, 7, 289.	2.4	11
439	Rates and predictors of one-year antipsychotic treatment discontinuation in first-episode schizophrenia: Results from an open-label, randomized, "real world" clinical trial. <i>Psychiatry Research</i> , 2019, 273, 631-640.	3.3	11
440	Rhythmic low-field magnetic stimulation may improve depression by increasing brain-derived neurotrophic factor. <i>CNS Spectrums</i> , 2019, 24, 313-321.	1.2	11
441	Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. <i>CNS Spectrums</i> , 2022, 27, 118-128.	1.2	11
442	Long-term outcome of early-onset compared to adult-onset schizophrenia: A nationwide Danish register study. <i>Schizophrenia Research</i> , 2020, 220, 123-129.	2.0	11
443	The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach. <i>BMC Psychiatry</i> , 2022, 22, 32.	2.6	11
444	Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs. <i>European Neuropsychopharmacology</i> , 2013, 23, 205-211.	0.7	10
445	Frequency of Hyperprolactinemia and Its Associations With Demographic and Clinical Characteristics and Antipsychotic Medications in Psychiatric Inpatients in China. <i>Perspectives in Psychiatric Care</i> , 2014, 50, 257-263.	1.9	10
446	Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. <i>BMC Psychiatry</i> , 2014, 14, 199.	2.6	10
447	SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics. <i>SpringerPlus</i> , 2014, 3, 187.	1.2	10
448	Creativity in persons at risk for bipolar disorder" A pilot study. <i>Microbial Biotechnology</i> , 2019, 13, 1165-1172.	1.7	10
449	Most recommended medical interventions reach $P \leq 0.005$ for their primary outcomes in meta-analyses. <i>International Journal of Epidemiology</i> , 2020, 49, 885-893.	1.9	10
450	Recognition of Patients Who Would Benefit From LAI Antipsychotic Treatment. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e29-e29.	2.2	10

#	ARTICLE	IF	CITATIONS
451	Understanding Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 8-13.	2.2	10
452	Real-Life Dosing With Second-Generation Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1610-1611.	2.2	10
453	Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms. <i>European Psychiatry</i> , 2022, 65, 1-27.	0.2	10
454	Prescribing of psychotropic medications to children and adolescents: <i>quo vadis</i>?. <i>World Psychiatry</i> , 2013, 12, 127-128.	10.4	9
455	Delayed identification and diagnosis of Huntingtonâ€™s disease due to psychiatric symptoms. <i>International Journal of Mental Health Systems</i> , 2015, 9, 33.	2.7	9
456	Could the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) be used in depressed schizophrenia patients?. <i>Journal of Affective Disorders</i> , 2015, 172, 191-194.	4.1	9
457	Insomnia in Adults With Chronic Hepatitis B, Liver Failure, and Cirrhosis: A Case-Control Study. <i>Perspectives in Psychiatric Care</i> , 2017, 53, 67-72.	1.9	9
458	Frequency and correlates of anticholinergic use among patients with schizophrenia in Denmark: A Nation-wide pharmacoepidemiological study. <i>Psychiatry Research</i> , 2017, 255, 198-203.	3.3	9
459	Better care for less money: costâ€ effectiveness of integrated care in multiâ€ episode patients with severeâ€ psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2020, 141, 221-230.	4.5	9
460	Motor activity patterns can distinguish between interepisode bipolar disorder patients and healthy controls. <i>CNS Spectrums</i> , 2022, 27, 82-92.	1.2	9
461	Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview. <i>Journal of Psychopharmacology</i> , 2021, 35, 1081-1090.	4.0	9
462	Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , 2021, 47, 986-996.	4.3	9
463	Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 774-784.	4.3	9
464	Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2023, 53, 4064-4082.	4.5	9
465	Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 535-547.	1.3	8
466	Attitudes towards and rationale for antipsychotic polypharmacy among psychiatrists in Nigeria: Characteristics associated with high reported antipsychotic polypharmacy. <i>Psychiatry Research</i> , 2017, 248, 134-139.	3.3	8
467	Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1109-1116.	1.9	8
468	Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. <i>Psychiatry Research</i> , 2019, 274, 176-181.	3.3	8

#	ARTICLE	IF	CITATIONS
469	Adapting to the impact of COVID-19 on mental health: an international perspective. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 229-233.	2.4	8
470	Demographic and Clinical Characteristics, Including Subsyndromal Symptoms Across Bipolar-Spectrum Disorders in Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 222-234.	1.3	8
471	What is the Best Latent Structure of Negative Symptoms in Schizophrenia? A Systematic Review. <i>Schizophrenia Bulletin Open</i> , 2021, 2, sgab013.	1.7	8
472	Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort. <i>Translational Psychiatry</i> , 2021, 11, 360.	4.8	8
473	Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials. <i>BMJ Open</i> , 2014, 4, e005708.	1.9	8
474	The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. <i>Focus (American Psychiatric Publishing)</i> , 2020, 18, 456-465.	0.8	8
475	Epidemiology and Prevention of Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1426.	2.2	8
476	Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis. <i>Frontiers in Psychiatry</i> , 2022, 13, 795866.	2.6	8
477	Switching and Combining Antipsychotics. <i>CNS Spectrums</i> , 2010, 15, 8-11.	1.2	7
478	Predicting and preventing bipolar disorder: the need to fundamentally advance the strategic approach. <i>Bipolar Disorders</i> , 2014, 16, 451-454.	1.9	7
479	Premature Mortality and Schizophrenia—The Need to Heal Right From the Start. <i>JAMA Psychiatry</i> , 2016, 73, 535.	11.0	7
480	Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. <i>Psychopharmacology</i> , 2018, 235, 681-693.	3.1	7
481	Longitudinal outcomes in pediatric and adult-onset bipolar patients compared to healthy and schizophrenia controls. <i>Bipolar Disorders</i> , 2019, 21, 514-524.	1.9	7
482	DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2020, 11, 568982.	2.6	7
483	Cariprazine in the management of negative symptoms of schizophrenia: state-of-the-art and future perspectives. <i>Future Neurology</i> , 2020, 15, .	0.5	7
484	Early Antipsychotic Nonresponse as a Predictor of Nonresponse and Nonremission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2022, , .	0.5	7
485	Lifetime prevalence and clinical correlates of nonsuicidal self-injury in youth inpatients with eating disorders: a retrospective chart review. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2022, 16, 17.	2.5	7
486	The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations. <i>European Neuropsychopharmacology</i> , 2022, 59, 45-55.	0.7	7

#	ARTICLE	IF	CITATIONS
487	Outcomes During and After Early Intervention Services for First-Episode Psychosis: Results Over 5 Years From the RAISE-ETP Site-Randomized Trial. <i>Schizophrenia Bulletin</i> , 2022, 48, 1021-1031.	4.3	7
488	Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 368-378.	0.8	6
489	The Field of Schizophrenia: Strengths, Weaknesses, Opportunities, and Threats. <i>Schizophrenia Bulletin</i> , 2012, 38, 1-4.	4.3	6
490	Efficacy of Pharmacologic and Psychotherapeutic Interventions in Psychiatry. <i>JAMA Psychiatry</i> , 2014, 71, 624.	11.0	6
491	A functional polymorphism in the interleukin-1beta and severity of nicotine dependence in male schizophrenia: A case-control study. <i>Journal of Psychiatric Research</i> , 2015, 64, 51-58.	3.1	6
492	Catecholâ€œMethyltransferase (COMT) Val158Met Polymorphism and Eating Disorders: Data From a New Biobank and Metaâ€œAnalysis of Previously Published Studies. <i>European Eating Disorders Review</i> , 2017, 25, 524-532.	4.1	6
493	Psychological and nutritional correlates of objectively assessed physical activity in patients with anorexia nervosa. <i>European Eating Disorders Review</i> , 2020, 28, 559-570.	4.1	6
494	Development of a Symptom-Focused Model to Guide the Prescribing of Antipsychotics in Children and Adolescents: Results of the First Phase of the Safer and Targeted Use of Antipsychotics (SUAY) Clinical Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, , .	0.5	6
495	Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis. <i>NPJ Schizophrenia</i> , 2021, 7, 41.	3.6	6
496	Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1158-e1166.	2.2	6
497	Identification of High-Risk Coronary Heart Disease Patients Receiving Atypical Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 578-583.	2.2	6
498	An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 537-540.	3.2	6
499	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. <i>Lancet Psychiatry</i> , 2022, 9, 291-306.	7.4	6
500	Outcomes of a Standardized, High-Caloric, Inpatient Re-Alimentation Treatment Protocol in 120 Severely Malnourished Adolescents with Anorexia Nervosa. <i>Journal of Clinical Medicine</i> , 2022, 11, 2585.	2.4	6
501	Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings. <i>Evidence-Based Mental Health</i> , 2017, 20, e6-e6.	4.5	5
502	Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gainâ€œReply. <i>JAMA Psychiatry</i> , 2017, 74, 1173.	11.0	5
503	O5.1. CLOZAPINE AND LONG-TERM MORTALITY RISK IN PATIENTS WITH SCHIZOPHRENIA: PRELIMINARY RESULTS FROM A META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S86-S86.	4.3	5
504	Assessment of Physical Activity Patterns in Adolescent Patients with Anorexia Nervosa and Their Effect on Weight Gain. <i>Journal of Clinical Medicine</i> , 2020, 9, 727.	2.4	5

#	ARTICLE	IF	CITATIONS
505	Exploring Movement Impairments in Patients With Parkinson's Disease Using the Microsoft Kinect Sensor: A Feasibility Study. <i>Frontiers in Neurology</i> , 2020, 11, 610614.	2.4	5
506	Systematic identification and stratification of help-seeking school-aged youth with mental health problems: a novel approach to stage-based stepped-care. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 781-793.	4.7	5
507	Clinical validation of the Symptom Self-rating Scale for Schizophrenia (4S) among inpatients. <i>Nordic Journal of Psychiatry</i> , 2021, 75, 454-464.	1.3	5
508	Emotional abuse interacts with borderline personality in adolescent inpatients with binge-purging eating disorders. <i>Eating and Weight Disorders</i> , 2022, 27, 131-138.	2.5	5
509	Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review. <i>European Neuropsychopharmacology</i> , 2022, 54, 90-99.	0.7	5
510	Symptoms and Characteristics of Youth Hospitalized for Depression: Subthreshold Manic Symptoms Can Help Differentiate Bipolar from Unipolar Depression. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 545-552.	1.3	5
511	Long-term efficacy and safety of once-monthly Risperidone ISMÂ® in the treatment of schizophrenia: Results from a 12-month open-label extension study. <i>Schizophrenia Research</i> , 2022, 239, 83-91.	2.0	5
512	Frequency and Correlates of Distant Visual Impairment in Patients with Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. <i>East Asian Archives of Psychiatry</i> , 2015, 25, 115-21.	0.4	5
513	Reliability and Validity of the Bipolar Prodrome Symptom Interview and Scale-Full Prospective in Its Turkish Translation. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 178-186.	1.3	5
514	Randomized controlled trial of cognitive remediation therapy in adolescent inpatients with anorexia nervosa: Neuropsychological outcomes. <i>European Eating Disorders Review</i> , 2022, 30, 772-786.	4.1	5
515	Polypharmacy in Youth Treated With Antipsychotics: Do Antidepressants or Stimulants Add to the Risk for Type 2 Diabetes?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 634-635.	0.5	4
516	Mullerian inhibiting substance, sex hormone binding globulin and sex hormone levels in stimulant-naïve, first-diagnosed prepubertal boys with attention-deficit/hyperactivity disorder: comparison with matched healthy controls as well as before and after oros-methylphenidate treatment. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 251-257.	2.4	4
517	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 83-94.	3.2	4
518	Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 141-145.	2.2	4
519	Dietary Consumption Among Youth with Antipsychotic-Induced Weight Gain and Changes Following Healthy Lifestyle Education. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 364-375.	1.3	4
520	Impact of Lurasidone and Other Antipsychotics on Body Weight: Real-World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia. <i>International Journal of General Medicine</i> , 2021, Volume 14, 4081-4094.	1.8	4
521	Identifying strategies to improve PANSS based dimensional models in schizophrenia: Accounting for multilevel structure, Bayesian model and clinical staging. <i>Schizophrenia Research</i> , 2021, , .	2.0	4
522	The Role of the Extended Health Care Team in Successful LAI Therapy. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e25.	2.2	4

#	ARTICLE	IF	CITATIONS
523	Symptomatic Presentation and Initial Treatment for Schizophrenia in Children and Adolescents. <i>Journal of Clinical Psychiatry</i> , 2010, 71, e29.	2.2	4
524	Extent, Time Course, and Moderators of Antipsychotic Treatment in Youth With Mood Disorders. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 347-357.	2.2	4
525	Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review. <i>Shanghai Archives of Psychiatry</i> , 2016, 28, 241-252.	0.7	4
526	Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia. <i>JAMA Psychiatry</i> , 2021, , .	11.0	4
527	Reasons for admission and variance of body weight at referral in female inpatients with anorexia nervosa in Germany. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2021, 15, 78.	2.5	4
528	Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia. <i>European Psychiatry</i> , 2022, 65, 1-35.	0.2	4
529	Drug-drug interactions involving antipsychotics and antihypertensives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 285-298.	3.3	4
530	Pharmacological Management of Bipolar Disorder in a Youth With Diabetes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 1375-1379.	0.5	3
531	Prioritization of Research Addressing Antipsychotics for Adolescents and Young Adults With Bipolar Disorder. <i>Annals of Internal Medicine</i> , 2014, 160, 492.	3.9	3
532	A new class of VMAT-2 inhibitors for tardive dyskinesia. <i>Lancet Psychiatry</i> , the, 2017, 4, 574-575.	7.4	3
533	M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY. <i>Schizophrenia Bulletin</i> , 2020, 46, S214-S214.	4.3	3
534	Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	3
535	Current and Novel Approaches to Mitigate Cardiometabolic Adverse Effects of Second-Generation Antipsychotics. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 491-495.	2.1	3
536	Frequency and Correlates of Acute Dystonic Reactions After Antipsychotic Initiation in 441 Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 366-375.	1.3	3
537	How to Estimate QT Interval in Patients With Left or Right Bundle Branch Block. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 323-326.	1.4	3
538	Early detection of bipolar disorders and treatment recommendations for help-seeking adolescents and young adults: Findings of the Early Detection and Intervention Center Dresden. <i>International Journal of Bipolar Disorders</i> , 2021, 9, 23.	2.2	3
539	What are the physical and mental health implications of duration of untreated psychosis?. <i>European Psychiatry</i> , 2021, 64, e46.	0.2	3
540	Diagnostic stability in children and adolescents with bipolar disorder, a nationwide register-based study. <i>International Journal of Bipolar Disorders</i> , 2020, 8, 14.	2.2	3

#	ARTICLE	IF	CITATIONS
541	Long-Acting Injectable Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2018, 79, AL17017WC1C.	2.2	3
542	Long-term safety and effectiveness of open-label lurasidone in antipsychotic-Naïve versus previously treated adolescents with Schizophrenia: A post-hoc analysis. <i>Schizophrenia Research</i> , 2022, 240, 205-213.	2.0	3
543	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 201-219.	2.2	3
544	Lack of cardinal symptoms of meningitis in a hospitalized patient with chronic schizophrenia: lessons to be learned. <i>General Hospital Psychiatry</i> , 2015, 37, 621.e3-621.e4.	2.4	2
545	Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study. <i>PLoS ONE</i> , 2019, 14, e0210674.	2.5	2
546	Standardized training in the rating of the six-item Positive And Negative Syndrome Scale (PANSS-6). <i>Schizophrenia Research</i> , 2021, 228, 438-446.	2.0	2
547	Efficacy of Lurasidone in Antipsychotic-Naive vs. Antipsychotic-Exposed Adolescents with Schizophrenia: Post-Hoc Analysis of a Two-Year, Open-Label Study. <i>CNS Spectrums</i> , 2021, 26, 147-147.	1.2	2
548	Long-acting injectable versus oral antipsychotics for schizophrenia – Authors' reply. <i>Lancet Psychiatry</i> , 2021, 8, 567.	7.4	2
549	Measurement-based Diagnosis and Treatment for Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	2
550	CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12–17 Years, With First Episode Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 667-672.	1.4	2
551	The Impact of Inpatient Multimodal Treatment or Family-Based Treatment on Six-Month Weight Outcomes in Youth with Anorexia Nervosa: A Naturalistic, Cross-Continental Comparison. <i>Nutrients</i> , 2022, 14, 1396.	4.1	2
552	Evidence-based flying taking off: maximising the effectiveness of a novel airline user decision-making tool. <i>International Journal of Clinical Practice</i> , 2010, 64, 1836-1837.	1.7	1
553	Review: most antipsychotic drugs more than double the prolactin levels in children and adolescents. <i>Evidence-Based Mental Health</i> , 2010, 13, 54-54.	4.5	1
554	Translation and adaptation of the Bipolar Prodrome Symptom Scale-Retrospective: Patient Version to Brazilian portuguese. <i>Trends in Psychiatry and Psychotherapy</i> , 2013, 35, 62-75.	0.8	1
555	Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 221-223.	3.8	1
556	A simulations approach for meta-analysis of genetic association studies based on additive genetic model. <i>Meta Gene</i> , 2018, 16, 143-164.	0.6	1
557	Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it) Tj ETQq1 1 0.784314 rgBT /Overlock 1	4.5	1
558	Clozapine and COVID-19: The authors respond. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, E1-E2.	2.4	1

#	ARTICLE	IF	CITATIONS
559	100 Olanzapine/Samidorphan for Schizophrenia: Weight Gain and Metabolic Outcomes in Phase 3 ENLIGHTEN-2 and Subsequent Long-Term, Open-Label Safety Study. <i>CNS Spectrums</i> , 2020, 25, 265-265.	1.2	1
560	Cardiometabolic Safety of Lumateperone (ITI~007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study in Schizophrenia. <i>CNS Spectrums</i> , 2021, 26, 152-152.	1.2	1
561	Occurrence and accuracy of a register-based diagnosis of pediatric bipolar disorder: A nationwide cohort study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 1101-1108.	2.3	1
562	Discrepancies between staff and gold standard ratings of schizophrenia symptom severity. <i>Psychiatry Research</i> , 2021, 301, 113963.	3.3	1
563	Huntington~s Disease With Psychotic Features. primary care companion for CNS disorders, <i>The</i> , 2021, 23, .	0.6	1
564	Diagnostic and Treatment Fundamentals for Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	1
565	Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2245-2263.	1.8	0
566	Ask the Expert: Schizophrenia. <i>Focus (American Psychiatric Publishing)</i> , 2012, 10, 154-156.	0.8	0
567	Importando la Escala de S~ntomas Prodr~micos Bipolares-Prospectiva Completa.. <i>Psiquiatria Biologica</i> , 2015, 22, 30-31.	0.1	0
568	O7.2. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION IN A CLINICAL COHORT. <i>Schizophrenia Bulletin</i> , 2018, 44, S93-S94.	4.3	0
569	S98. THE RELATIONSHIP BETWEEN CARDIOVASCULAR RISK FACTORS AND COGNITIVE IMPAIRMENT IN PEOPLE WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S363-S363.	4.3	0
570	144 A Clinical Practice Assessment In Tardive Dyskinesia: Are Physicians Up-to-Date?. <i>CNS Spectrums</i> , 2018, 23, 89-90.	1.2	0
571	Mobility for All?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, 792-793.	0.5	0
572	Disturbing Lack of Early Intervention Studies in Bipolar Disorder~"Reply. <i>JAMA Psychiatry</i> , 2018, 75, 1202.	11.0	0
573	S46. THE VALIDITY AND SENSITIVITY OF PANSS-6 IN TREATMENT-RESISTANT SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018, 44, S341-S342.	4.3	0
574	S27. RELIABILITY OF SCHIZOPHRENIA DIAGNOSES IN CHILDREN AND ADOLESCENTS IN DENMARK. <i>Schizophrenia Bulletin</i> , 2018, 44, S333-S333.	4.3	0
575	Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia. <i>Evidence-Based Mental Health</i> , 2018, 21, e11-e11.	4.5	0
576	O12.1. CARDIOMETABOLIC ADVERSE EFFECTS AND ITS PREDICTORS IN CHILDREN AND ADOLESCENTS WITH FIRST-EPISEDE PSYCHOSIS DURING TREATMENT WITH QUETIAPINE-ER VERSUS ARIPIPRAZOLE: 12-WEEK RESULTS: FROM THE TEA TRIAL. <i>Schizophrenia Bulletin</i> , 2019, 45, S197-S197.	4.3	0

#	ARTICLE	IF	CITATIONS
577	84 Assessment of Current Clinical Practices in Recognizing and Treating Bipolar Disorder. CNS Spectrums, 2019, 24, 217-218.	1.2	0
578	Measuring movements in adolescents with psychosis using the Microsoft Kinect sensor: a pilot study exploring a new tool for assessing aspects of antipsychotic-induced parkinsonism. Child and Adolescent Mental Health, 2020, 25, 79-94.	3.5	0
579	Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brain-related functional pathways. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2020, 183, 140-151.	1.7	0
580	Cultural Influences in Psychiatry Reply. JAMA - Journal of the American Medical Association, 2020, 323, 1193.	7.4	0
581	104 Long-term Efficacy of Lurasidone in Antipsychotic-naïve vs. Antipsychotic-exposed Adolescents with Schizophrenia: Analysis of a Two-Year Study. CNS Spectrums, 2020, 25, 267-268.	1.2	0
582	Systematic review of transdermal treatment options in attention-deficit/hyperactivity disorder: implications for use in adult patients. CNS Spectrums, 2021, , 1-13.	1.2	0
583	Validity of the Aktibipo Self-rating Questionnaire for the Digital Self-assessment of Mood and Relapse Detection in Patients With Bipolar Disorder: Instrument Validation Study. JMIR Mental Health, 2021, 8, e26348.	3.3	0
584	Long-acting antipsychotics: is what we know really so? Authors' reply. Lancet Psychiatry, the, 2021, 8, 651-652.	7.4	0
585	Withdrawal-associated relapse is a potential source of bias Authors' reply. Lancet Psychiatry, the, 2021, 8, 748-749.	7.4	0
586	Pediatric Schizophrenia. , 2013, , 1-6.		0
587	Drs Kane and Correll Reply. Journal of Clinical Psychiatry, 2020, 81, .	2.2	0
588	Unleashing the power of pooled and subgroup analyses in psychiatry. International Clinical Psychopharmacology, 0, Publish Ahead of Print, .	1.7	0
589	Characteristics prior to and at time of diagnosis in pediatric bipolar disorder. Nordic Journal of Psychiatry, 2023, 77, 282-292.	1.3	0